{
  "document_type": "research_report",
  "extraction_data": {
    "company_name_short": "艾迪药业",
    "company_code": "688488",
    "report_title": "艾迪药业(688488) 公司发布期权激励，双轨考核助力抗艾新药快速放量，维持“买入”评级",
    "investment_rating": "买入",
    "core_thesis": "分析师看好公司抗艾滋病新药持续快速放量，其“治疗+预防”的全面布局有望提升估值。同时，公司通过控股南大药业，打造人源蛋白业务作为第二成长曲线。预计2025年起，“HIV新药+人源蛋白”双轮驱动将推动公司业绩持续向好。",
    "profit_forecast": [
      {
        "year": 2025,
        "metric": "归母净利润",
        "value": "-2000000.0",
        "yoy_growth": null
      },
      {
        "year": 2026,
        "metric": "归母净利润",
        "value": "44000000.0",
        "yoy_growth": null
      },
      {
        "year": 2027,
        "metric": "归母净利润",
        "value": "88000000.0",
        "yoy_growth": "100.0"
      }
    ],
    "valuation": [
      {
        "year": 2025,
        "metric": "PS",
        "value": 8.4
      },
      {
        "year": 2026,
        "metric": "PS",
        "value": 6.0
      },
      {
        "year": 2027,
        "metric": "PS",
        "value": 5.0
      }
    ],
    "comparable_companies": [],
    "risk_factors": [
      "行业政策变化",
      "HIV新药销售不达预期",
      "竞争格局变动的风险"
    ],
    "business_concepts": [
      {
        "concept_name": "抗HIV药物",
        "concept_category": "核心业务",
        "description": "公司的核心业务，抗艾新药正处于快速放量阶段。核心产品艾诺米替（ACC008）临床数据显示其安全性和有效性良好，有利于提升患者依从性。在研整合酶抑制剂ACC017片有望于2025年内开启III期临床。公司同时布局暴露前预防（PrEP）药物，形成“治疗+预防”的全面产品组合。新的期权激励计划也设定了明确的HIV药物营收目标（2025年目标4亿元，2026年目标6亿元）以驱动销售增长。",
        "importance_score": 0.9,
        "development_stage": "成长期",
        "timeline": {
          "established": null,
          "recent_event": "2025年Q1销售额创历史新高，在研产品ACC017有望年内开启III期临床。"
        },
        "metrics": {
          "revenue": 62000000.0,
          "revenue_growth_rate": 75.64,
          "market_share": null,
          "gross_margin": null,
          "capacity": null,
          "sales_volume": null
        },
        "relations": {
          "customers": [],
          "partners": [],
          "subsidiaries_or_investees": []
        },
        "source_sentences": [
          "2025Q1HIV新药销售6200万元（同比+75.64%），单季业绩创历史新高，商业化运作进展积极。",
          "ACC008临床研究证据不断完善，在0~144周艾诺米替持续治疗组治疗依从和病毒学抑制率均高于95%；在48~144周，自艾考恩丙替转换至艾诺米替治疗依从性和病毒学抑制率均高于93%。",
          "在研管线方面，公司整合酶抑制剂ACC017片正在进行Ⅱ期临床数据整理，2025年内有望开启III期临床；公司加速抗HIV长效预防药物研发，布局暴露前预防适应症；"
        ],
        "key_products_or_brands": [
          "艾诺米替",
          "ACC008",
          "ACC017片"
        ]
      },
      {
        "concept_name": "人源蛋白业务",
        "concept_category": "战略布局",
        "description": "通过收购南大药业的重大资产，公司实质性地深度布局人源蛋白业务，旨在将其打造成公司的第二成长曲线，与现有的HIV业务形成互补和协同效应。",
        "importance_score": 0.75,
        "development_stage": "并购整合期",
        "timeline": {
          "established": null,
          "recent_event": "近期通过收购南大药业重大资产进入该领域。"
        },
        "metrics": {
          "revenue": null,
          "revenue_growth_rate": null,
          "market_share": null,
          "gross_margin": null,
          "capacity": null,
          "sales_volume": null
        },
        "relations": {
          "customers": [],
          "partners": [],
          "subsidiaries_or_investees": [
            "南大药业"
          ]
        },
        "source_sentences": [
          "同时公司收购南大药业重大资产，实质推动公司深度布局人源蛋白业务，打造公司第二成长曲线。",
          "我们预计2025年公司“HIV新药＋人源蛋白”业务齐头并进，业绩持续向好。"
        ],
        "key_products_or_brands": []
      },
      {
        "concept_name": "急性缺血性脑卒中药物",
        "concept_category": "新兴业务",
        "description": "公司的在研管线之一，2.2类改良型新药AD108注射液，目前正在进行I期临床试验，旨在用于改善急性缺血性脑卒中所致的神经功能缺损。",
        "importance_score": 0.3,
        "development_stage": "探索期",
        "timeline": {
          "established": null,
          "recent_event": "目前正在进行I期临床试验。"
        },
        "metrics": {
          "revenue": null,
          "revenue_growth_rate": null,
          "market_share": null,
          "gross_margin": null,
          "capacity": null,
          "sales_volume": null
        },
        "relations": {
          "customers": [],
          "partners": [],
          "subsidiaries_or_investees": []
        },
        "source_sentences": [
          "公司2.2类改良型新药AD108注射液开展“拟用于改善急性缺血性脑卒中所致的神经功能缺损”的I期临床。"
        ],
        "key_products_or_brands": [
          "AD108注射液"
        ]
      }
    ]
  },
  "extraction_metadata": {
    "model_version": "gemini-2.5-pro-preview-06-05",
    "prompt_version": "1.0.0",
    "extraction_timestamp": "2025-07-20T18:28:54.281599",
    "processing_time_seconds": 51.65492796897888,
    "token_usage": {
      "input_tokens": 0,
      "output_tokens": 0,
      "total_tokens": 0
    },
    "file_hash": "33239802c476a97beba73645f357d7ae13fbe88c44a8dd33dddbafcfef51bd83"
  },
  "raw_llm_response": ""
}